SynAct Pharma AB (8F8)

Overview

SynAct Pharma AB operates as a clinical stage biotechnology firm, focusing on the discovery and development of pharmaceutical solutions for inflammatory diseases. Founded in 2012, the company is actively engaged in advancing its pipeline of drug candidates, with its efforts centralized in Lund, Sweden. Through its commitment to innovation, SynAct Pharma AB aims to address the unmet medical needs of patients suffering from a variety of inflammatory conditions.

Products and Services

• AP1189

  AP1189 serves as the flagship drug candidate of SynAct Pharma AB, primarily targeted at the treatment of rheumatoid arthritis. It also shows potential in treating idiopathic membranous nephropathy, a rare kidney disorder, and virus-induced respiratory insufficiency. Currently undergoing clinical trials, AP1189 represents the company’s dedication to providing novel therapeutic options for complex inflammatory diseases.

• TXP-11

  In the early stages of development, TXP-11 is an advanced peptide agonist gearing towards preclinical trials. Its main focus is the prevention of organ failures during complicated surgeries. This drug embodies SynAct Pharma’s commitment to extending its research and development beyond traditional inflammatory and autoimmune diseases, venturing into critical care medicine.

• Auto-Immune Disease Programs

  SynAct Pharma is actively working on several drug programs targeting auto-immune diseases. These programs are at various stages of development, reflecting the company’s broad approach to tackling auto-immunity through innovative therapeutic strategies. The specifics of these programs highlight the depth of the company's research capabilities and its dedication to addressing auto-immune conditions with novel solutions.